Author

A. Closa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

E. Eyras· 3 shared R. W. Stam· 2 shared A. Bataller· 1 shared A. C. Fuentes-Fayos· 1 shared A. Enders· 1 shared A. Thomas-Tikhonenko· 1 shared B. Boast· 1 shared C. Bueno· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Eyras

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A comprehensive single-cell expression atlas of human AML leukemia-initiating cells unravels the contribution of HIF pathway and its therapeutic potential

T. Velasco-Hernandez, J. L. Trincado, M. Vinyoles, A. Closa, F. Gutierrez-Aguera, O. Molina, V. C. Rodriguez-Cortez, P. Petazzi, S. Beneyto-Calabuig, L. Velten, P. Romecin, R. Casquero, F. Abollo-Jimenez, R. Diaz de la Guardia, P. Lorden, , P. Menendez

The paper creates a single-cell atlas of AML leukemia-initiating cells and shows that targeting the HIF pathway enhances chemotherapy effectiveness against these cells.

bioRxiv · Mar 2, 2022 · PreprintCancer Biology

A convergent malignant phenotype in B-cell acute lymphoblastic leukemia involving the splicing factor SRRM1

A. Closa, M. Reixachs-Sole, A. C. Fuentes-Fayos, K. E. Hayer, J. L. Melero, F. R. Adriaanse, R. S. Bos, M. Torres-Diz, S. Hunger, K. G. Roberts, C. Mullighan, R. W. Stam, A. Thomas-Tikhonenko, J. P. Castano, R. M. Luque, E. Eyras

The paper identifies a convergent malignant phenotype in infant B-ALL linked to SRRM1 upregulation and splicing alterations, independent of gene fusions.

bioRxiv · Dec 13, 2021 · PreprintCancer Biology

Dysregulation of PAX5 causes uncommitted B cell development and tumorigenesis in mice

B. Boast, K. Helian, D. Andrews, X. Li, V. Cho, A. Closa, H. J. Sutton, J. H. Reed, H. Bergmann, C. M. Roots, M. Yabas, N. Barthel, S. A. Omari, C. Young, L. A. Miosge, , A. Enders

Reduced PAX5 function in mice leads to uncommitted B cell development and B-ALL with secondary mutations in Jak3 and Ptpn11.

bioRxiv · Jan 29, 2021 · PreprintImmunology